Actualizado 03/09/2010 11:42
- Comunicado -

Fresenius Medical Care and SEHA Enter Into Exclusive Agreement to Serve Dialysis Patients in Abu Dhabi

BAD HOMBURG, Germany, September 3, 2010 /PRNewswire/ -- Fresenius Medical Care AG & Co. KGaA (Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS), the world's largest provider of dialysis products and services, today announced its signing of a nonbinding memorandum of understanding with Abu Dhabi Health Services Co. PJSC (SEHA), the public provider of health care services, for exclusive management of its dialysis facilities in the emirate of Abu Dhabi, United Arab Emirates.

The agreement will enable Fresenius Medical Care to initiate activities in a key Middle Eastern market. It also is aimed as a key aspect of both groups' strategy to expand their business in the region. Both entities have agreed not to disclose financial details of the transaction under discussion.

"Initiating patient care operations in the Middle East has been a defined path in our overall growth strategy, and we are convinced that the contract with SEHA is an excellent basis for the growth of Fresenius Medical Care in this region. The contract will allow our company to significantly strengthen its sales and distribution network and expand our presence in this key market," said Fresenius Medical Care's Dr. Emanuele Gatti, CEO for Europe, Latin America, the Middle East and Africa.

Saif Bader Al Qubaisi, managing director and chairman of SEHA, commented, "We are delighted to have engaged Fresenius Medical Care as our exclusive partner in the management of our renal patients. We look forward to benefiting from the knowledge and skills of the leader in this sector in building a world-class patient care organization that delivers on its promise of high-quality health care services for the people. We also look forward to pursuing other development activities in the region with our partner Fresenius Medical Care."

Dr. Ali Abdulkareem Al Obaidli, chief of clinical affairs for SEHA and a practicing renal specialist, added, "This is good news for Abu Dhabi. Bringing in the world's best providers and managers is part of our business strategy. This partnership will result in improved service levels and better outcomes for our dialysis patients."

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1.89 million individuals worldwide. Through its network of 2,599 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 202,414 patients around the globe. Fresenius Medical Care also is the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P).

For more information about Fresenius Medical Care, visit the company's website at http://www.fmc-ag.com.

About the SEHA HealthSystem and Abu Dhabi Health Services Co. PJSC (SEHA)

Abu Dhabi Health Services Co. PJSC is an independent, public joint-stock company wholly owned by the government of Abu Dhabi and created to develop the curative activities of the emirate's public health care system. The company owns and operates all the public hospitals and clinics in the emirate of Abu Dhabi which together make up the SEHA HealthSystem. Its holdings include 12 hospitals with 2,644 beds, 62 ambulatory care, family care and urgent care centers and two blood banks. SEHA is one of the largest integrated health care providers in the Middle East, employing 16,500 doctors, nurses, ancillary care and administrative personnel. SEHA means "health" in Arabic. Visit the SEHA website at http://www.seha.ae.

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

    
    Joachim Weith
    Corporate Communications and Governmental Affairs
    Tel.: +49-6172-6082101
    Fax: +49-6172-6082294
    E-mail: pr@fmc-ag.com
    http://www.fmc-ag.com

Joachim Weith, Corporate Communications and Governmental Affairs, Tel.: +49-6172-6082101, Fax: +49-6172-6082294, E-mail: pr@fmc-ag.com

Comunicados

Si quieres mejorar el posicionamiento online de tu marca, ahora puedes publicar tus notas de prensa o comunicados de empresa en la sección de Comunicados de europa press

Si necesitas asesoramiento en comunicación, redacción de tus notas de prensa o ampliar la difusión de tu comunicado más allá de la página web de europa press, ponte en contacto con nosotros en comunicacion@europapress.es o en el teléfono 913592600